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Prebiotic supplementation in frail older
people affects specific gut microbiota taxa
but not global diversity
Tam T. T. Tran1,2†, Fabien J. Cousin1,2†, Denise B. Lynch1,2†, Ravi Menon7, Jennifer Brulc7, Jillian R.-M. Brown1,2,
Eileen O’Herlihy1,2, Ludovica F. Butto1,2,3, Katie Power1,6, Ian B. Jeffery1,2, Eibhlís M. O’Connor1,4,5 and
Paul W. O’Toole1,2*
Abstract
Background: There are complex interactions between aging, frailty, diet, and the gut microbiota; modulation of
the gut microbiota by diet could lead to healthier aging. The purpose of this study was to test the effect of diets
differing in sugar, fat, and fiber content upon the gut microbiota of mice humanized with microbiota from healthy
or frail older people. We also performed a 6-month dietary fiber supplementation in three human cohorts
representing three distinct life-stages.
Methods: Mice were colonized with human microbiota and then underwent an 8-week dietary intervention with
either a high-fiber/low-fat diet typical of elderly community dwellers or a low-fiber/high-fat diet typical of long-stay
residential care subjects. A cross-over design was used where the diets were switched after 4 weeks to the other
diet type to identify responsive taxa and innate immunity changes. In the human intervention, the subjects
supplemented their normal diet with a mix of five prebiotics (wheat dextrin, resistant starch, polydextrose, soluble
corn fiber, and galactooligo-saccharide) at 10 g/day combined total, for healthy subjects and 20 g/day for frail
subjects, or placebo (10 g/day maltodextrin) for 26 weeks. The gut microbiota was profiled and immune responses
were assayed by T cell markers in mice, and serum cytokines in humans.
Results: Humanized mice maintained gut microbiota types reflecting the respective healthy or frail human donor.
Changes in abundance of specific taxa occurred with the diet switch. In mice with the community type microbiota,
the observed differences reflected compositions previously associated with higher frailty. The dominance of
Prevotella present initially in community inoculated mice was replaced by Bacteroides, Alistipes, and Oscillibacter. Frail
type microbiota showed a differential effect on innate immune markers in both conventional and germ-free mice,
but a moderate number of taxonomic changes occurring upon diet switch with an increase in abundance of
Parabacteroides, Blautia, Clostridium cluster IV, and Phascolarctobacterium. In the human intervention, prebiotic
supplementation did not drive any global changes in alpha- or beta-diversity, but the abundance of certain
bacterial taxa, particularly Ruminococcaceae (Clostridium cluster IV), Parabacteroides, Phascolarctobacterium, increased,
and levels of the chemokine CXCL11 were significantly lower in the frail elderly group, but increased during the
wash-out period.
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Conclusions: Switching to a nutritionally poorer diet has a profound effect on the microbiota in mouse models,
with changes in the gut microbiota from healthy donors reflecting previously observed differences between elderly
frail and non-frail individuals. However, the frailty-associated gut microbiota did not reciprocally switch to a younger
healthy-subject like state, and supplementation with prebiotics was associated with fewer detected effects in
humans than diet adjustment in animal models.
Keywords: Aging, Microbiome, Prebiotics, Gut microbiota, Elderly, Innate immune response
Background
Diet has an important role in shaping gut microbiota com-
position and function. Numerous studies have reported an
association between consumption of non-digestible fiber in-
gredients (e.g., prebiotics) and increased levels of reputedly
beneficial bacteria in the gut such as Ruminococcaceae,
Bifidobacterium, Lactobacillus, Faecalibacterium, and
Roseburia [1–4]. An overview of 2099 participants from 64
studies revealed a significant increase in the abundance of
bacteria from the genera Bifidobacterium and Lactobacillus
as well as higher levels of fecal butyrate concentration
following dietary fiber intervention, particularly involving
fructans and galacto-oligosaccharides, compared with pla-
cebo/low-fiber comparators [5]. Similarly, the consumption
of resistant starch has been shown to enrich Ruminococcus
bromii and Eubacterium rectale [6]. The gut microbiota
interacts with the human immune system and microbiota
alterations have been linked to various inflammatory,
metabolic, or functional disorders such as type 2 dia-
betes, obesity, and irritable bowel syndrome [7–9]. One
of the mechanisms implicated in immune modulation is
gut microbiota fermentation of dietary fibers to produce
short-chain fatty acids (SCFAs) [10]. Studies of the Medi-
terranean diet showed that a diet rich in fruit, legumes,
and vegetables affected the abundance of certain gut bac-
teria, increased levels of fecal SCFAs [11], and reduced
inflammation in Crohn’s disease [12]. In contrast, a low-
carbohydrate diet was associated with increased abun-
dance of Streptococcus, Lactococcus, and Eggerthella, and
lower abundance of carbohydrate-degrading bacteria
(Ruminoccocus, Eubacterium, Clostridium, and Bifidobac-
terium), resulting in reduction in fecal concentrations of
SCFAs [13]. Moreover, a progressive loss of microbial
diversity was observed in mice colonized with a human
microbiota consuming a low-fiber diet over generations,
which was not recoverable after the reintroduction of
dietary fiber [14].
Changes in the gut microbiome are also associated with
aging [15–17]. In our previous studies, we described the
relationship between aging, frailty, diet, and the gut micro-
biota. Microbiota composition was a strong co-variate of
measures of frailty, comorbidity, nutritional status, and
markers of inflammation [15, 16]. A reduction in
abundance of particular taxa such as Ruminococcus and
Prevotella in the elderly, with an associated increase in
Alistipes and Oscillibacter, correlated with several indices
of frailty, and we reported a direct correlation between
values of the healthy food diversity (HFD) index (dietary
diversity as well as amount and health-promoting value of
consumed food [18]) and gut microbiota alpha diversity
(gut microbiota richness within individuals) in both com-
munity and long-stay subjects [15, 17]. Levels of inflam-
matory markers including TNF-α, IL-6, and IL-8 and
C-reactive protein (CRP) are higher in long-stay and re-
habilitation subjects than in community dwellers [15].
Moreover, as hypothesized frequently and summarized in
a recent review [19], the gut microbiota may play a key
role in age-related inflammation.
Based on the evidence reviewed above, gut microbiota
modulation by diet is a potential approach for extending
health span in the elderly. In this study, we investigated
whether gut microbiota transfer from older, healthy
community-dwelling, and long-term residential care
individuals could be stably established and maintained in
mice fed a customized diet; whether these microbiota
compositions would respond to dietary modification; and
if there was an effect upon innate immunity markers. In
addition, a dietary intervention in elderly subjects and
young-healthy controls was conducted to determine if
prebiotic supplementation could modulate gut microbiota
composition and reduce inflammation in the elderly.
Results
Establishment and dietary programming of elderly donor
gut microbiota in mice
Conventional mice that had been treated with a cocktail
of five antibiotics (ampicillin, vancomycin, ciprofloxacin,
imipenem, metronidazole) for 6 weeks, and germ-free
mice, were humanized with cryo-preserved fecal material
(see “Methods” section) from frail (long-stay) or healthy
(community dwelling) elderly donors. The fecal micro-
biota was sampled at critically informative time-points,
namely just before antibiotic treatment, in the week
following humanization, after 4 weeks on the first
experimental diet, in the week after diet swap (week 5),
and at the end of the second diet period (week 8)
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(Fig. 1). To examine diet-microbiome interaction in mice
of human microbiota corresponding to different older
health strata, we commissioned the production of two
synthetic diets (Table 1). The main differences between
the two diets was a higher proportion of sugars,
meat-derived ingredients, and fats that provide 3.6 kcal/g
in the long-stay-based diet, whereas higher amounts of
starches, fibers, and fish products provide 4.5 kcal/g in the
community-based diet, which contained an additional
284 g/kg of dietary fiber and 38 g/kg cellulose. The mice
were allowed to feed ad libitum from 8 g fresh feed pro-
vided daily.
Beta diversity (PCoA) analysis showed that the micro-
biota of the pre-treatment conventional mice was very
distinct from that of the human donors whose datasets
grouped together on this phylogenetic distance scale
Fig. 1 Schematic diagram of experimental design in murine intervention study. Arrows indicate the week on which the fecal samples were collected
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(Fig. 2a). However, when sampled 1 week after inocula-
tion, the microbiota of the humanized mice was closer
to that of the microbiota of the human donors and
remained stable for 4 weeks on the diet emulating the
healthy human diet. On the scale where all samples are
mapped (Fig. 2a), it is not possible to see changes
between later weeks, but nevertheless it is clear that the
microbiota of the colonic scrapings, colonic contents, and
caecal contents at week 8 are close to that of the fecal
microbiota at week 8. Even though the bacterial commu-
nity composition differed among these groups at week 8,
the microbial communities from the feces and colonic
contents are more similar to each other than are the co-
lonic scrapings and caecal contents in both conventional
mice and germ-free mice (Additional file 1: Figure S1).
These findings confirm that the fecal analysis is a good
proxy for luminal gut microbiota analysis in this context.
Fine-scale PCoA analysis (Fig. 2b) revealed that the
microbiota of mice colonized with material from a long-
stay donor, as expected, was separate from that of mice
that received fecal microbiota from a health community
donor. After 4 weeks, the murine diets were swapped.
After only 1 week (i.e., by week 5) on the high-fat low-
fiber long-stay type diet, the community-colonized mouse
microbiota moved noticeably in the PCoA toward that of
the long-stay colonized mice. The microbiota of the
long-stay colonized mice switched to a “healthy” diet
moved away from the community quadrant after
1 week, and over half the samples continued in that
direction from weeks 5 to 8, while a minority con-
verged toward the community-mice on the low-fiber
high-fat long-stay diet. Between weeks 5 and 8, the
community-colonized mice fed a low-fiber high-fat
long-stay-based diet moved back into their original
Table 1 Composition of community-based diet and long-stay-based diet
Community-based diet Long-stay-based diet
g/kg g/kg
Ingredients
Sucrose 160 330
Corn starch 62.7 101.5
Maltodextrin 50 90
High amylose corn starch 150 0
RS3-resistant starcha 100 0
Cellulose 43 5.2
Soluble corn fiberb 36 1.5
L-cystine 3 3
Casein 63 0
Fish meal, menhaden 88.5 0
Meat and bone meal (50%) 0 85
Poultry meal, low ash (11%) 81 160
Soybean oil 25 15
Lard 60 96
Coconut oil, hydrogenated 20 55
Mineral Mix, AIN-93G-MX 40 40
Vitamin Mix, AIN-93-VX 15 15
Choline bitartrate 2.75 2.75
Thiamin HCl 0.013 0.013
Vitamin K1, phylloquinone 0.002 0.002
TBHQ, antioxidant 0.014 0.014
Selected nutrient (% kcal)
Protein 18.5 13.9
Carbohydrate 50.7 47.1
Fat 30.8 38.9
RS3 resistance starch type 3, TBHQ tert-butylhydroquinone
bPromitor soluble fiber (Tate & Lyle Lafayette, Indiana, USA)
aNovelose 330 (Ingredion, Indianapolis, Indiana, USA)
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side of the PCoA plot but did not revert to their ori-
ginal position.
Microbiota composition analysis and identification of
differentially abundant taxa between time points revealed
that antibiotic treatment and inoculation led to successful
engraftment of the human microbiota. Moreover, genus
abundance changes were associated with diet change.
Community-inoculated mice that were transferred to the
low-fiber high-fat long-stay-based diet showed an increase
in the relative abundance of Bacteroides, Alistipes,
Pseudoflavonifractor, Oscillibacter, Clostridium cluster
XI, Desulfovibrio, and Butyricimonas and a decrease in
Prevotella abundance (Additional file 1: Figure S2a).
Long-stay inoculated mice showed an increase in abun-
dance of Parabacteroides and Marvinbryantia and a
decrease in Prevotella, Flavonifractor, Oscillibacter,
Clostridium cluster XI, Desulfovibrio, and Butyricimonas
when switched to the high-fiber low-fat community-based
diet (Additional file 1: Figure S2b).
Similar analyses were performed in germ-free mice
that had been colonized, their microbiota monitored for
4 weeks, and then subjected to dietary swap. Microbiota
composition was initially distinct, reflecting that of the
two human microbiota donor types, but switched based
on the change of diet (Additional file 1: Figure S3). Simi-
lar to the conventional animals, the low-fiber high-fat
long stay-based diet switch in the animals inoculated
with community-type microbiota had a greater impact
on the gut microbiota than did the change to the
community-based diet in long-stay colonized animals
a b
c d
Fig. 2 Principle coordinates analysis plots based on Spearman distances colored by time point. Samples from conventional mice cross over
design: a all samples; b week 4, 5, and 8 samples. Samples from germ-free mice cross over design: c all samples, d week 4, 5 and 8 samples. The
significant differences between groups were calculated by analysis of similarity (ANOSIM) tests. CM donor healthy community subject, LS donor
frail long-stay subject, ColS colonic scraping, ColC colonic content, CaeC caecal content, W week, W-7 (week minus 7) murine microbiota before
antibiotic treatment
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(Fig. 2c, d). Thus, the long-stay type microbiota was
relatively non-responsive to the introduction of the
high-fiber low-fat community-based diet. However, spe-
cific responses (Additional file 1: Figure S3b) included
increased proportions of the health-associated taxa
Blautia and Clostridium cluster IV and decreased rela-
tive abundance of Parasutterella (which is associated
with induced colitis [20]) and Bacteroides.
In order to compare success of engraftment of the hu-
man microbiota in the two mouse models, we examined
the datasets at week 1 after inoculation and compared
the number of observed genera with those in the inocu-
lating donor stool (Additional file 2: Table S1). Of the 54
genera observed in the stool of the long-stay donor, 46
were detected in at least 1 germ-free mouse, whereas 45
genera were detected in at least 1 antibiotic-treated con-
ventional mouse. We then set a threshold that at least
50% of the recipient mice must harbor the genus to be
considered successful engraftment. By this criterion, 36
genera were successfully engrafted in the germ-free
mice, whereas only 26 were successfully introduced into
the antibiotic-treated conventional mice. Six genera were
found in germ-free mouse stool that were not present in
the donor stool, and four of those were found in 50% of
the mice, presumably acquired from the environment
post humanization. However, 26 genera were found in
antibiotic-treated conventional mice that were not found
in the donor stool, although only 1 of these was found
in a minimum of 50% of the mice. Applying a similar
analysis to the community donor inoculum, of the 46
genera observed in the community donor inoculum, 37
were successfully engrafted into any antibiotic-treated
conventional mice but only 33 were engrafted into the
germ-free mice. Of those, 22 were engrafted into 50% of
the antibiotic-treated conventional mice, although 27 were
engrafted into 50% of the germ-free mice. Twenty-one
genera were found in the antibiotic-treated conventional
mice stools that were not found in the donor stool, 4 of
which were found in 50% of mice, whereas 18 genera were
found in the germ-free mice that were not found in the
donor, 10 of which were found in 50% of mice. More gen-
erally, while similar numbers of genera engraft in any type
of mouse, engraftment appears successful in a higher
proportion of germ-free mice than conventional mice.
Conventional mice were also carrying higher numbers of
non-transferred genera, presumably having survived anti-
biotic treatment.
Differential effects of healthy and frail microbiota types
on innate immunity in mice
Next, we investigated the differential effect of introducing
the two elderly subject microbiota types on the murine
innate immune system. Spleen mononuclear cells isolated
from long-stay inoculated mice in both the crossover de-
sign and non-crossover design experiments showed higher
level expression of many T cell markers associated with
inflammation, compared to mice receiving fecal inoculum
from a healthy community dwelling subject. In particular,
the long-stay inoculated conventional mice, non-crossover
design, presented higher proportions of CD11c-expressing
dendritic cells and F4/80-expressing macrophages, and
lower proportions of CD8+ T cells. However, in the cross-
over design, we observed an increased abundance of
CD4+ T regulatory cells and Ly6G+ neutrophils in the
long-stay inoculated conventional mice. An increased pro-
portion of CD11c expressing cells was also noted in the
long-stay inoculated germ-free mice (Fig. 3a). After sple-
nocyte stimulation, the long-stay inoculated conven-
tional mice had higher TNF-α levels in the supernatant
than the community-microbiota inoculated mice. We
also detected higher TNF-α expression levels after
LPS-K12 and LTA-SA stimulation in the long-stay type
microbiota-inoculated mice compared to community in-
oculated mice in the conventional mouse non-crossover
design. Similar observations were found for TNF-α level
after stimulation and even in RPMI control in the conven-
tional mouse crossover design. No difference in TNF-α
levels between diet-microbiota treatment groups was
observed and a very high level of responses to all three
stimuli was measured in germ-free mice (Fig. 3b).
Design and implementation of a prebiotic
supplementation trial in human subjects
Prebiotic compounds which can be metabolized by a
subset of intestinal bacteria are a recognized way of
modulating the microbiota [21]. Since the microbiota of
frail long-stay subjects displays loss of certain taxa, it
might be possible to “remediate” this by prebiotic sup-
plementation. We surveyed the literature then available
for microbiota effects of prebiotics, focusing mainly on
trials in older humans (Table 2), ingredient type, and to-
lerated dosage, cognizant of the challenge of introducing
prebiotics in the diet of the elderly [22]. Collectively,
these compounds had been shown in previous studies
(Table 2) to promote the growth of a diverse range of
health associated taxa, including those depleted in the
low-diversity microbiota of frail older people. We thus
designed a daily supplement containing five prebiotic in-
gredients of which almost half were resistant starch, an
ingredient known to promote growth of health-related
taxa in the gut microbiota [6]. The placebo treatment
was 10.5 g/day of maltodextrin, previously shown to
have relatively low effect of the gut microbiota [23]. As
well as comparison to maltodextrin effects, each subject
acted as their own control because the main focus was
microbiota comparison pre- and post-intervention. After
Tran et al. Microbiome            (2019) 7:39 Page 6 of 17
a 2-week lead-in, the trial was conducted for 6 months
(26 weeks) with a 6-week washout after which further
microbiota analysis was performed.
To provide additional comparative value, we recruited
three treatment groups: young-healthy subjects, elderly
community subjects (a healthy elderly group), and elderly
long-stay subjects, descriptive statistics for which are
shown in Table 3. We aimed to have 20 treated sub-
jects and 10 placebo controls in each of the 3 arms.
This recruitment ratio of 2 to 1 was designed to
a
b
Fig. 3 Splenocyte phenotypes and TNF-α response profiles of mice inoculated with a community microbiota and mice inoculated with a long-
stay microbiota in conventional mice (CNV) and germ-free (GF) mice. a Immunostaining of splenocytes. b TNF-α response after splenocyte
stimulation with RPMI complete medium as control (RPMI) or with bacterial surface compounds including LPS from Escherichia coli K12 (LPS-Ec),
LTA from Staphylococcus aureus (LTA-Sa) or from Bacillus subtilis (LTA-Bs). P values were calculated using the Mann-Whitney U test,
*p < 0.05; **p < 0.001
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Table 2 Selection, source, and dosage of prebiotic ingredients for dietary supplementation
Ingredient
[Reference]
Trial Outcomes Supplier/product code g/
mix
Wheat
dextrin [43]
Intensive care unit
patients (~ 65 years)
10–22 g/day × 2–5
weeks
Increase in Firmicutes, butyrate-producing bacteria (Eubacterium hallii,
Eubacterium rectale, Roseburia intestinalis, Clostridia cluster XIVa), starch
degrading bacteria (Ruminococcus bromii, Ruminococcus obeum, Sporobacter
terminitidis), Fecalibacterium prausnitzii, Bifidobacterium spp., & SCFA levels
Ingredion/Nutriose FB 06 3
Resistant
starch [24]
Rats 10%–20 weeks Reduced incidence of colon carcinogenesis possibly through an increase
in butyrate
Ingredion/Novelose 330 10
Polydextrose
[3]
Healthy males
(20–40 years)
21 g/day × 21 days
Increase in Faecalibacterium, Phascolarctobacterium and Dialister Danisco/Litesse 3
Soluble corn
fiber [3]
Healthy males
(20–40 years)
21 g/day × 21 days
Increase in Faecalibacterium, Phascolarctobacterium, Dialister, Roseburia and
Lactobacillus
Tate and Lyle/ SCF
22–5421/Promitor soluble
fiber 85
3
Galactooligo-
saccharide [4]
Healthy humans
(19–50 years)
5–10 g/day × 16 weeks
Bifidogenic, increase in Fecalibacterium prausnitzii and Actinobacteria and
reduction in Bacteroides
Friesland Campina/Vivinal
GOS
2
Total max daily
supplement
21
Table 3 Clinical characteristics of the subjects, grouped by residence location, at baseline
Characteristics Young-healthy Community Long-stay pb
Intervention Placebo pa Intervention Placebo pa Intervention Placebo pa
n 21 8 20 8 17 5
Sex (#male:female) 6:15 7:1 0.01 7:13 3:5 1.00 7:10 2:3 1.00 0.808
Age (years) 41.9 (14.5) 33.1 (13.2) 0.09 69.5 (4.9) 74.9 (7.5) 0.07 83.4 (7.6) 85 (7.6) 0.84 < 0.001
BMI (kg/cm2) 24.7 (5.0) 25.7 (3.5) 0.31 26.2 (4.3) 25.5 (1.4) 0.76 27.3 (6.2) 28.8 (7.7) 0.82 0.157
Weight (kg) 70.6 (13.5) 80.4 (10.6) 0.06 74.7 (14.9) 66.2 (8.8) 0.13 80 (28.1) 90.7 (28.5) 0.46 0.665
Charlson comorbidity ND ND ND 0 (0) 0.1 (0.4) 0.13 2 (1.3) 3 (3.0) 0.75 < 0.001
Barthel score ND ND ND 20 (0) 19.9 (0.4) 0.13 6.6 (5.5) 5 (3.5) 0.72 < 0.001
ALP (IU/L) 73.8 (26.0) 90.5 (24.6) 0.10 80.8 (16.6) 74.4 (17.7) 0.41 106.2 (28.9) 101.5 (39.3) 0.79 0.002
ALT (IU/L) 25.1 (12.6) 26.5 (5.9) 0.29 23.8 (10.9) 24 (7.7) 0.58 13.9 (7.2) 12.5 (4.5) 0.86 < 0.001
AST (IU/L) 25.2 (4.5) 28.8 (6.8) 0.19 27.3 (7.1) 31.2 (13.6) 0.94 19 (4.9) 16 (3.2) 0.33 < 0.001
Bilirubin (μmol/L) 14.1 (10.6) 10.9 (5.0) 0.45 12.1 (5.8) 11.1 (4.5) 0.75 6.5 (2.0) 7 (2.4) 0.65 < 0.001
Total cholesterol (mmol/L) 5.5 (0.7) 5.7 (1.1) 0.90 5.5 (1.2) 5.1 (1.2) 0.49 4.5 (0.9) 4.8 (1.9) 0.87 0.004
HDL-cholesterol (mmol/L) 1.5 (0.3) 1.4 (0.3) 0.15 1.6 (0.3) 1.8 (1.2) 0.30 1.2 (0.3) 1.1 (0.2) 0.64 0.001
LDL-cholesterol (mmol/L) 3.4 (0.6) 3.6 (0.9) 0.59 3.5 (1.2) 2.9 (0.8) 0.29 2.6 (0.8) 2 (0.8) 0.40 0.004
Triglycerides (mmol/L) 1.3 (0.5) 1.5 (0.6) 0.59 1.2 (0.4) 1.3 (0.3) 0.33 1.7 (0.8) 2.8 (1.9) 0.23 0.030
Fasting glucose (mmol/L) 4.5 (0.6) 4.5 (0.5) 0.48 5.2 (0.7) 5 (0.6) 0.49 6.1 (1.6) 7.7 (2.8) 0.22 < 0.001
Creatinine (μmol/L) 71.5 (12.2) 80.9 (15.8) 0.07 70.1 (14.4) 76.1 (23.3) 0.52 91 (48.0) 104.5 (38.9) 0.59 0.068
Ferritin (μg/L) 73.8 (48.5) 98.1 (64.5) 0.39 102.6 (63.2) 107.6 (53.7) 0.61 80.9 (70.7) 40.3 (10.1) 0.79 0.094
TSH (mIU/L) 1.9 (0.8) 1.6 (0.3) 0.39 2.5 (1.3) 2.4 (1.3) 0.92 1.7 (0.6) 1.1 (1.0) 0.30 0.037
Urea (mmol/L) 5.4 (1.1) 5.5 (1.2) 0.96 5.7 (1.4) 5.5 (1.0) 0.58 8.7 (3.6) 11.6 (4.1) 0.11 < 0.001
Vitamin B12 (pg/mL) 265.1 (159.3) 318.8 (120.6) 0.12 332.6 (153.3) 303.4 (93.4) 0.79 234.2 (119.5) 195.7 (46.6) 0.63 0.009
White blood cell count 6 (1.6) 6.1 (1.4) 0.79 5.5 (1.1) 6.2 (1.7) 0.47 7.3 (2.6) 6.9 (0.7) 0.90 0.042
HFD index 0.5 (0.1) 0.4 (0.1) 0.031 0.4 (0.1) 0.4 (0.1) 0.409 0.3 (0.1) 0.4 (0.1) 0.179 < 0.001
Data presented as mean (SD)
ALP alkaline phosphatase, ALT alanine aminotransferase, AST aspartate transaminase, TSH thyroid-stimulating hormone, HFD healthy food diversity, ND not done
aMann-Whitney U test for two treatment groups except Fisher’s test for sex ratio
bKruskal-Wallis test for three residence location groups
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provide the optimal number of samples so that alter-
ations due to the treatment could be detected and
characterized, while also allowing us to recruit and
sample a placebo group. However, only 69 subjects out
of 93 recruited participants (74.1%) completed the
study, due to a combination of infraction of exclusion
criteria; death due to unrelated causes (5.4%, n = 5);
withdrawal at the investigators’ discretion, usually
because of deteriorating health (5.4%, n = 5); self-with-
drawal due to unspecified personal reasons (9.7%, n =
9); loss to follow up (2.1%, n = 2); or inability to pro-
duce samples (3.2%, n = 3) (Additional file 2: Table
S2). As expected, the three cohorts showed signifi-
cantly different clinical status, especially the young-
healthy/community and long-stay with respect to age,
frailty (Charlson comorbidity index, Barthel index),
HFD value, and other clinical markers except BMI and
sex (Table 3). However, within each cohort, there was
no significant difference between intervention and
placebo arms at baseline except sex ratio and HFD
index in the young-healthy group due to skewed with-
drawal of females from the placebo group (Table 3).
Compliance/dosage received varied widely especially
in long-stay subjects (Fig. 4). Rather than losing
participants from the study, tolerance was monitored
weekly, and after the first 13-week period, the daily pre-
biotic intake was reduced if required in long-stay interven-
tion subjects. 16S rRNA gene amplicon sequencing was
used to profile the microbiota of available subjects/sam-
ples at each time point (see Additional file 2: Table S3).
Limited effect of prebiotic supplementation on gut
microbiota
The microbiota alpha diversity of long-stay subjects was
significantly lower than that in community and young-
healthy subjects, but there were no significant differences
in alpha diversity within residence location for treatment
groups at baseline except in Chao1, community group
(Additional file 1: Figure S4). Bray-Curtis distance PCoA
showed that fecal microbial profiles of long-stay subjects
were separated significantly from those of community and
young-healthy at baseline, in line with our previous stu-
dies [15] (Additional file 1: Figure S5). No statistically
significant difference in alpha- and beta-diversity was
found between time points within treatment groups
(Additional file 1: Figures S6, S7). Furthermore, there
was no significant interaction between the dosage re-
ceived and alpha diversity within each intervention
treatment groups (Additional file 2: Table S4), sug-
gesting that an overall treatment effect on microbiota
diversity was not being masked by the range of pre-
biotic dosage received. Variations in the relative abun-
dances of numerous fecal microbiota taxa were
detected in individuals over time points and between
individuals (Additional file 1: Figure S8). Analysis
using DESeq2 identified 15 families and 34 genera
that were differentially abundant between time points
in treatment groups (Fig. 5, Additional file 3: Tables S5,
S6), without a clear treatment effect for most. However,
among these, several taxa were commonly associated with
intervention or placebo treatment. Notably, increased
Fig. 4 Average intake of dietary supplement per day as an intervention or placebo across subjects from week 0 to week 13, and week 13 to
week 26. YH young-healthy, CM community, LS long-stay
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abundance was observed for some bacteria after prebiotic
supplementation such as Ruminococcaceae (Clostridium
cluster IV), Parabacteroides, and Phascolarctobacterium
(Additional file 1: Figure S9). In addition, to examine the
common signature associated with the prebiotic and
placebo interventions, we conducted an analysis on all
available intervention or placebo samples regardless of
life-stage. Seven taxa representing one unclassified
Ruminococcaceae and six genera were significantly dif-
ferentially abundant across all placebo-treated subjects,
but were not significantly different in the individual co-
horts except Pseudomonas (Additional file 1: Figure S10).
In contrast, 11 taxa representing 2 unclassified and 8
genera were significantly altered in abundance in the pre-
biotic intervention subjects. There taxa were consistently
returned between the individual cohorts and the combined
analysis with all identified genera being differentially abun-
dant in at least one of the life-stage intervention cohorts.
Immunological/inflammatory biomarker changes
associated with prebiotic supplementation
Persistent inflammation is associated with less healthy
aging and was a target for reduction by dietary modulation
of the gut microbiota. Levels of cytokines and inflamma-
tory biomarkers (CRP, CXCL11, CCL11) were higher at
baseline in long-stay subjects than in community and
young-healthy subjects (Table 4). Levels of IL-17A, IL6,
TNF-α, and lipopolysaccharide (LPS) were higher in com-
munity dwelling elderly participants than in young-healthy
subjects (recognizing the limitation that the reporter cell
assay for LPS was sensitive to other molecules that might
trigger NFkB activation). There was no significant differ-
ence between groups at baseline in proportion of CD4+
cells, while CD8+ levels were higher in young-healthy sub-
jects compared to others.
Within treatment groups, there was a significant
difference between time points in levels of CXCL11,
CCL11, IL-6, IL-8, TNF-α, CD8, and LPS (Add-
itional file 3: Table S7). Decreased plasma CXCL11 level
tended to be associated with intervention treatment
while the opposite pertained for IL-6 and CD4+ mea-
sures (Fig. 6). CXCL11 levels in supplemented long-stay
subjects increased during the washout period, consis-
tent with a treatment reduction effect. Decreased plasma
CCL1 levels and CD8+ counts were positively associated
with prebiotic supplementation in young-healthy subjects.
Fig. 5 Significantly differential abundant taxa at family and genus level in any time points within treatment groups. Adjusted p values were
calculated by DESeq2 test with Benjamini–Hochberg correction. YH young-healthy, CM community, LS long-stay
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Measures of IL-8, TNF-α, and LPS differed significantly
between time points in both intervention and placebo
subjects (Additional file 1: Figure S11).
Discussion
Our previous studies suggested that programming of the
gut microbiota by habitual diet might contribute to
microbiota changes associated either causally or conse-
quentially with loss of health in older people. In this
study, we sought to clarify these possibilities by micro-
biota transfer to mice in which we could dramatically
manipulate the diet, and in humans where more modest
dietary alteration could be performed. Our data indicate
that dietary programming is possible, confirming other
studies in animals and humans [3, 24], although not as
responsive in our pre-clinical models as in published
studies of humans [25, 26]. In humans, the prebiotic
supplementation had relatively modest effects on the
microbiota and achieved some alteration of innate
immune markers that may be beneficial in the elderly.
This effect could be direct, i.e., not microbiota-mediated,
by mechanisms including the prebiotic compounds
binding to host metabolites, or being absorbed directly
into intestinal cells and changing the expression level of
cytokine genes [27].
To search for coherent signals between the current
study and our previous analyses of microbiota in the
elderly, taxa whose abundance changed significantly
after dietary swap in mice were plotted on to a network
of bacterial Co-abundance groups (CAGs) that we pre-
viously generated [15] (Fig. 7a) from the ELDERMET
cohort. This data visualization graphically highlights the
fact that the dominant genera associated with the CAGs
in the original human cohort changed in abundance in
the humanized mice after the diet swap in a way that
was consistent with the compositional differences be-
tween healthy community-dwelling subjects’ microbiota
and the long-stay type microbiota in the ELDERMET
cohort. These transitions were associated with the reduc-
tion of fiber in both conventional and germ-free mice hu-
manized with microbiota from healthy community-dwelling
subjects. After dietary modification, the dominance of
Prevotella presented initially in community inoculated
mice was replaced by Bacteroides, Alistipes, and Oscilli-
bacter. Although we observed decline of Bacteroides,
Alistipes, and Oscillibacter in long-stay inoculated mice
fed with the high-fiber/low-fat diet, the gut microbiota
did not revert to a Prevotella-dominated configuration.
Long-stay type taxa were instead replaced by other taxa
including Parabacteroides, Blautia, Clostridium cluster
IV, and Phascolarctobacterium (Fig. 7). Most taxonomic
changes could be explained by ingredients associated
with the diet types. The Bacteroides enterotype was
strongly associated with protein and animal fat intake,
while the Prevotella enterotype was associated with
carbohydrates and simple sugars [25]. None of the fiber
ingredients in the community-based diet that we used
here has previously been reported to promote Prevotella,
although the dominance of this genus, which was evident
in community dwellers, might possibly be achieved by a
long-term experimental diet regime. Parabacteroides and
Phascolarctobacterium were positively associated with
soluble corn fiber intake [3, 28], and both became more
abundant in both murine and human intervention studies
with soluble corn fiber supplementation. We also found
that Oscillibacter, Clostridium cluster XI, Desulfovibrio,
Table 4 Comparison of immunological/inflammatory biomarkers between residence location groups at baseline
Biomarkers pa pb Mean (SD)
CM vs. YH CM vs. LS YH vs. LS YH CM LS
CRP (mg/L) < 0.001 0.443 < 0.001 (↑) < 0.001 (↑) 2 (3.8) 1.5 (1.2) 24.3 (29.2)
CXCL11 (pg/ml) < 0.001 0.244 < 0.001 (↑) < 0.001 (↑) 345.8 (594.6) 670.3 (1310.9) 1278.1 (1655.1)
CCL11 (pg/ml) < 0.001 0.126 < 0.001 (↑) < 0.001 (↑) 12.1 (27.3) 17.5 (37.3) 310.3 (133.3)
IL-17A (pg/ml) < 0.001 < 0.001 (↓) 0.002 (↑) < 0.001 (↑) 0.4 (0.0) 0.9 (0.5) 3.4 (2.9)
IFN-γ (pg/ml) 0.004 0.094 0.026 (↑) < 0.001 (↑) 5 (6.4) 6.4 (6.5) 10.5 (8.4)
IL-10 (pg/ml) < 0.001 0.365 < 0.001 (↑) < 0.001 (↑) 0.1 (0.1) 0.1 (0.1) 0.8 (1.9)
IL-6 (pg/ml) < 0.001 0.006 (↓) < 0.001 (↑) < 0.001 (↑) 0.2 (0.1) 0.6 (0.4) 3.1 (3)
IL-8 (pg/ml) 0.008 0.113 0.033 (↑) < 0.001 (↑) 8.9 (5.1) 12.9 (14.2) 29.1 (67.4)
TNF-α (pg/ml) < 0.001 0.012 < 0.001 (↑) < 0.001 (↑) 1 (0.6) 1.7 (0.8) 5.1 (2.8)
CD4 (%) 0.342 0.113 0.097 0.448 38.6 (7.8) 33.5 (13) 37.8 (16.3)
CD8 (%) 0.001 < 0.001 (↑) 0.167 0.006 (↓) 20.9 (6.6) 13.6 (9.5) 16.5 (10.6)
LPS (EU/ml) 0.065 0.010 (↓) 0.129 0.173 6.1 (4.7) 11 (8.3) 8.2 (7.0)
↑ ↓ Indicates direction of difference in value in the latter-named group, in the pairwise comparison
CM community (seniors), YH young-healthy, LS long-stay (residential care seniors)
aKruskal-Wallis test across the three residence location groups
bDunn’s post-hoc test for pairwise comparison
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and Butyricimonas were more abundant in mice receiving
the low-fiber/high-fat diet and decreased in abundance
after a high-fiber/low-fat diet, largely consistent with pre-
vious murine studies [29–31]. A limitation of the current
mouse study is that the inoculum for each dietary group
was provided by one donor. Given the continuum of
inter-donor variability when examining the human gut
microbiota, it is possible that inoculating mice with feces
from a different donor could generate a different response.
However, pooling donors would produce artificial com-
munities capable of unrealistic dietary responses.
Some of the observations from the animal study were also
evident in the human intervention, with Parabacteroides
abundance increased shortly after at the start of the
intervention in the young, community, and long-stay
groups, reaching statistically significant elevation in the
latter two groups. Clostridium cluster IV abundance
also increased soon after the start of the intervention
in all three groups and was significantly elevated in the
young controls and the long-stay elderly subjects.
Several of the limited taxa identified as responsive in the
human trial have previously been demonstrated to be
Fig. 6 Serum CXCL11 and IL-6 levels, and CD4+ T cell proportions were different between time points within treatment groups. P values were
calculated from Wilcoxon signed-rank test. *p < 0.05. YH young-healthy, CM community, LS long-stay, T0 baseline (week 0), T13 halfway (week 13),
T26 end of study (week 26), T32 6 weeks after the cessation of treatment (week 32)
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affected by prebiotics. We observed increased abundance of
the family Ruminococcaceae, well-characterized butyrate-
producing bacteria, in long-stay subjects after prebiotic
supplementation. Ruminococcaceae were positively asso-
ciated with resistant starch intake in a pilot study of 14
obese males [2]. Similarly, Phascolarctobacterium was
more abundant post-intervention in long-stay intervention
subjects, and this genus was previously identified in
healthy adult men consuming soluble corn fiber [3]. In
contrast, the abundances of Bifidobacterium, Lactobacillus,
Dialister, Faecalibacterium, and Roseburia were not altered
by the supplementation, compared to the reported
response of these bacteria to prebiotics [1, 3, 4, 7]. In the
long-stay subjects, Bifidobacterium abundance actually
decreased (Additional file 1: Figure S9). These findings
can perhaps be explained by the quantity of ingredients
in the prebiotic-supplemented regime with half of the
prebiotic mix as resistant starch and the remaining half
comprising the four other prebiotics. Furthermore,
although we tested for dosage correlation, the differences
in intervention dosage between long-stay subjects may
have affected our ability to associate significant taxon
changes with the intervention.
Our previous studies suggested that the gut microbiota
may interact with the innate immune system leading to in-
creased levels of inflammatory markers in long-stay sub-
jects compared to community dwellers [15]. Supporting
this hypothesis, we found an increased expression level of
immune cell markers (CD11c, F4/80) and TNF-α levels,
and a decrease of T cell CD8 expression in long-stay
inoculated mice. These findings are not inconsistent with
the fact that CD11c, F4/80, CD8, and TNF-α play an
important role in host defense mechanisms against in-
vading pathogens [32], and the relative number of CD8+ T
cells decreases with age [33]. In the human trial, prebiotic
supplementation in long-stay subjects led to decreased
production of the chemokine CXCL11 that is produced in
response to microbial antigens [34]. Modulation of the
low diversity long-stay subject gut microbiome by
prebiotic supplementation may thus impact the immune
system, but the effects are clearly restricted in mediator
range, and the health/clinical benefits are not clear.
We did not perform shotgun metagenomic sequencing
of the gut microbiome of treated animals or human study
participants, and so changes in the metabolic capacity of
the microbiome or its host-interaction capability were not
detectable. Strain level differences in the microbiome that
we also could not detect can have important functional
interactions with diet [35]. Some participants withdrew
before finishing the study or were excluded due to low-
quality sequencing reads. For valid clinical reasons, some
subjects did not receive the same amount of prebiotic sup-
plementation and we were not able to maintain the target
dose of 21 g per day in long-stay subjects during the
6-month trial period. Compliance in the long-stay group
was challenging particularly because of heightened sensi-
tivity to bowel discomfort in less active subjects. Finally,
the small number of subjects in the placebo groups
especially in the long-stay cohort reduced statistical
power, but this limitation was operationally imposed by
the overall availability of eligible subjects especially
because of the antibiotic treatment exclusion criterion
in the older subjects.
Conclusion
The high abundance taxa in community type gut micro-
biota were altered by a high-fat/low-fiber diet in mouse
models and showed a progression toward a long-stay
type gut microbiota structure. The long-stay type gut
microbiota in the mouse model was perturbed by a
high-fiber diet as evidenced by taxonomic alterations as-
sociated with the dietary change but did not move to a
more community like structure. The combined evidence
suggests an association between gut microbiota, diet,
and immune response in animal models, but supplemen-
tation with prebiotics, at least with the supplementation
levels we were able to get participant acceptance of in
this study, had much weaker effects. It remains unclear
whether ingredients in the prebiotic mix act alone or in
combination to modulate the gut microbiome. Further
studies are needed to optimize the choice of components
combined in the prebiotic mix and to evaluate the effect
of the prebiotic mix on the human gut microbiome in
larger cohorts.
Methods
Human fecal inoculum preparation
Two human donors were selected from among community-
dwelling and long-stay residential care groups based on
their microbiota profiles from our previously published
[15]. Fresh feces were collected from these donors for use
in the murine intervention studies. Human stools were
transferred to an anaerobic chamber within 1 min of voi-
ding, transported to the lab in anaerobic bags, transferred
(See figure on previous page.)
Fig. 7 a Composition changes in gut microbiota at the genus level of conventional mice and germ-free mice inoculated with a community microbiota
or with a long-stay microbiota were associated with dietary change. Genera were projected on to a pre-existing network of co-abundance groups as
defined by Claesson et al. [15]. Circle sizes indicate genus abundance with arrow (↑ or ↓) indicating increases or decreases in taxon abundance in week 8
when compared to week 4. Associations between genera are represented by gray lines for positive and red lines for negative. b Schematic summary of
how selected changes in gut microbiota composition are associated with fiber supplementation
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to an anaerobic hood, and then diluted (ratio 1:10) in with
pre-reduced PBS containing 20% glycerol, before being ali-
quoted in 1 ml volumes in cryovials and stored at − 80 °C.
We compared these new samples to the donors’ previously
analyzed samples to ensure the same typical community or
long-stay microbiota profiles were observed (data not
shown). The same community inocula and the same
long-stay inocula were used for conventional mice
and germ-free mice.
Murine intervention study
The study was approved by the Animal Ethics Experimen-
tation Committee of University College Cork (Approval
number 2011/017). Two mouse models including conven-
tional C57 mice and germ-free Swiss Webster mice were
used for three studies. A schematic overview of the expe-
rimental study design is presented in Fig. 1. First, con-
ventional mice were treated with (1 g/l), vancomycin
(500 mg/l), ciprofloxacin (200 mg/l), imipenem (250 mg/l),
and metronidazole (1 g/l) as described previously [36] in
the drinking water for 6 weeks and were fed ad libitum
sterile standard chow which comprised 83.7% carbohy-
drate, 12.9% protein, and 2.5% fat (Special Diet Services,
UK, code: 801010) (Additional file 3: Table S8) after 1 week
of acclimation. In parallel, germ-free mice were fed stan-
dard chow diet till 3 weeks of age, then the customized
diet until 6 weeks old. After a 24-h antibiotic-free
period in conventional mice, all mice were inoculated
with human microbiota derived from a healthy commu-
nity subject or a frail long-stay subject (week 0) and main-
tained on a customized diet corresponding to community
or long-stay residence (community/long-stay-based diet)
with ad libitum access to food (8 g/day) for 4 weeks.
Animal weight and food intake were recorded. Then
mice were assigned to the opposite diet for a further
four weeks, until terminal sacrifice at week 9, in a
crossover design. The third study was conducted with
conventional mice, but they were sacrificed at week 4 for a
non-crossover design. Fecal samples were collected from
each animal at several time points: before the antibiotic
treatment (week − 7) for conventional mice, end of week
1, end of week 4, end of week 5, end of week 8. For some
animals, and a minority of timepoints, fecal samples could
not be collected. After sacrifice, luminal content from the
caecum and colon, and colonic scrapings, were collected
for microbiome analysis and spleen was isolated immedi-
ately for analysis of the immune response. Spleen cells
were stimulated for tumor necrosis factor alpha (TNF-α)
analysis and processed for flow cytometric analysis as
described in Additional file 4: Supplementary Methods.
Community/long-stay-based diets (as described in
Table 1) were formulated to mimic a low-fat/high-fiber
diet typical of healthy community-dwelling older people
and a high-fat/low-fiber diet of long-term residential
care older people from our previous findings [15], albeit
with artificially high-fiber content. Median frequencies
of consumption were calculated for the selected diet
from each group and the UK institutionalized and aged
65+ portion sizes applied [37]. Dietary analysis was
conducted using WISP© (Weighed Intake Software
Program; Tinuviel Software, Warrington, UK).
Human study subject recruitment and sample collection
Ethical approval and exclusion criteria used for subject
selection are described in Additional file 4: Supplemen-
tary Methods. Subjects in each cohort were randomized
to receive either a dietary supplement as an intervention
product, based on ingredients procured by General Mills
Inc., or a placebo (maltodextrin) manufactured by Nutri-
tion Supplies Services, Cork, Ireland. The intervention
dietary supplement provided to participants with a pre-
biotic mix (21 g) including wheat dextrin (3 g), resistant
starch (10 g), polydextrose (3 g), soluble corn fiber (3 g),
and galactooligo-saccharide (2 g), as per Table 2. A dietary
prebiotic supplement was administered to the partici-
pants. All subjects were instructed (or aided) to take the
supplement dose in the morning with food over 26 weeks.
Each dose consisted of 10.5 g of the placebo/prebiotic
powder. Subjects in the long-stay cohort who were re-
ported having a lower baseline dietary fiber intake [38]
took an additional dose of 10.5 g powder, equating to a
daily dose of 21 g powder.
Samples obtained from participants included stool,
whole blood, serum, urine, anthropometric measure-
ments, and clinical history at four time points: baseline
(week 0), halfway (week 13), end of study (week 26), and
6 weeks after the cessation of treatment (week 32). A
food frequency questionnaire (FFQ) was utilized to cal-
culate HFD index [18]. Non-fasted blood samples were
analyzed at Cork University Hospital clinical laborato-
ries. In addition, whole and coagulated bloods were col-
lected from all of the participants to further determine
inflammation and immune response, for the following
tests: surface staining for CD4 and CD8, serum for CRP,
lipopolysaccharide (LPS) assay, cytokines (IL-17, IFN-γ,
IL-10, IL-4, IL-6), and chemokines (CXCL11, CCL11).
See Additional file 4: Supplementary Methods for details.
16S rRNA gene sequencing, bioinformatic, and statistical
analysis
Microbial DNA was extracted, amplified, and sequenced
from fecal samples of mice and human as previously [39]
and further described in Additional file 4: Supplementary
Methods. All statistical analyses were performed using R
[40], described in Additional file 4: Supplementary Methods,
and briefly here. Differences in beta diversity were
investigated using analysis of similarity (ANOSIM).
Changes in alpha diversity were detected using linear
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mixed models (R package nlme [41]). Analysis of
variance (ANOVA) tests were used to investigate dosage
difference effects on alpha diversity in linear mixed
models. Differences in alpha diversity among cohorts
were compared by Wilcoxon signed rank test (paired
data), the Mann-Whitney U test (unpaired data), or the
Kruskal-Wallis test with Dunn’s multiple comparison
test. Differential abundance at phylum and genus level
among time points within treatment groups was identified
using DESeq2 [42] controlling for subject identity across
time-points and HFD-index differences, and adjusted
using Benjamini–Hochberg correction.
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